Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Directed phenotype switching as an effective antimelanoma strategy.
Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN. Sáez-Ayala M, et al. Among authors: middleton m. Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. Epub 2013 Jun 20. Cancer Cell. 2013. PMID: 23792190 Free article.
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X. Lu M, et al. Among authors: middleton mr. Cancer Cell. 2013 May 13;23(5):618-33. doi: 10.1016/j.ccr.2013.03.013. Epub 2013 Apr 25. Cancer Cell. 2013. PMID: 23623661 Free article.
Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.
Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X. Lu M, et al. Among authors: middleton mr. Cancer Cell. 2016 Nov 14;30(5):822-823. doi: 10.1016/j.ccell.2016.09.019. Cancer Cell. 2016. PMID: 27846394 Free article. No abstract available.
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, Siddaway R, Lisle R, Freter R, Daniels MJ, Lu X, Tüting T, Middleton M, Buffa FM, Willis AE, Pavitt G, Ronai ZA, Sauka-Spengler T, Hölzel M, Goding CR. Falletta P, et al. Among authors: middleton m. Genes Dev. 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116. Epub 2017 Jan 17. Genes Dev. 2017. PMID: 28096186 Free PMC article.
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K, Binet R, Lambert JP, Louphrasitthiphol P, Kalkavan H, Sesma-Sanz L, Robles-Espinoza CD, Sarkar S, Suer E, Andrews S, Chauhan J, Roberts ND, Middleton MR, Gingras AC, Masson JY, Larue L, Falletta P, Goding CR. Herbert K, et al. Genes Dev. 2019 Mar 1;33(5-6):310-332. doi: 10.1101/gad.314633.118. Epub 2019 Feb 25. Genes Dev. 2019. PMID: 30804224 Free PMC article.
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution.
Louphrasitthiphol P, Siddaway R, Loffreda A, Pogenberg V, Friedrichsen H, Schepsky A, Zeng Z, Lu M, Strub T, Freter R, Lisle R, Suer E, Thomas B, Schuster-Böckler B, Filippakopoulos P, Middleton M, Lu X, Patton EE, Davidson I, Lambert JP, Wilmanns M, Steingrímsson E, Mazza D, Goding CR. Louphrasitthiphol P, et al. Among authors: middleton m. Mol Cell. 2020 Aug 6;79(3):472-487.e10. doi: 10.1016/j.molcel.2020.05.025. Epub 2020 Jun 11. Mol Cell. 2020. PMID: 32531202 Free PMC article.
sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
Fane ME, Ecker BL, Kaur A, Marino GE, Alicea GM, Douglass SM, Chhabra Y, Webster MR, Marshall A, Colling R, Espinosa O, Coupe N, Maroo N, Campo L, Middleton MR, Corrie P, Xu X, Karakousis GC, Weeraratna AT. Fane ME, et al. Among authors: middleton mr. Clin Cancer Res. 2020 Nov 1;26(21):5709-5719. doi: 10.1158/1078-0432.CCR-20-0446. Clin Cancer Res. 2020. PMID: 33097493 Free PMC article.
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V. Chen JL, et al. Among authors: middleton m. Int J Cancer. 2015 Mar 15;136(6):E590-601. doi: 10.1002/ijc.29118. Epub 2014 Aug 14. Int J Cancer. 2015. PMID: 25081390 Free article. Clinical Trial.
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.
Findlay JM, Castro-Giner F, Makino S, Rayner E, Kartsonaki C, Cross W, Kovac M, Ulahannan D, Palles C, Gillies RS, MacGregor TP, Church D, Maynard ND, Buffa F, Cazier JB, Graham TA, Wang LM, Sharma RA, Middleton M, Tomlinson I. Findlay JM, et al. Among authors: middleton m. Nat Commun. 2016 Apr 5;7:11111. doi: 10.1038/ncomms11111. Nat Commun. 2016. PMID: 27045317 Free PMC article.
620 results